Edison Investment Research - Denbury Resources Inc. (DNR) QuickView: A great oil business, but not as you know it

Report

Edison Investment Research

QuickView: A great oil business, but not as you know it

Denbury Resources (DNR) specialises in monetising stranded oil from depleted oilfields in the US. The group achieves this via the large-scale injection and sweep of carbon dioxide (CO2) through reservoirs. Over the last 10 years DNR has developed a technical edge in implementing and managing CO2 floods, to the point of being a repeatable, proven process for the company. Its estimated 7.5tcf of natural CO2 deposits, combined with its technical expertise, has created a near monopoly for the company when acquiring depleted oil properties in the vicinity of its CO2 network.

21/04/2015 2 EN

Underlying

Denbury Resources Inc.

Denbury Resources is an independent oil and natural gas company. The company's operations are focused in two main operating areas: the Gulf Coast and Rocky Mountain regions. The company's properties with proved and producing reserves in the Gulf Coast region are situated in Mississippi, Texas, Louisiana and Alabama, and in the Rocky Mountain region are situated in Montana, North Dakota and Wyoming.

See profile

US2479162081 United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

GlobeNewsWire

Denbury Reports First Quarter 2021 Results

Denbury Reports First Quarter 2021 Results PLANO, Texas, May 06, 2021 (GLOBE NEWSWIRE) -- Denbury Inc. (NYSE: DEN) (“Denbury” or the “Company”) today provided results for the first quarter of 2021, including the following key outcomes: FIRST QUARTER 2021 HIGHLIGHTS Net cash provided by operating activities was $53 million; Adjusted cash flow from operations(1) (non-GAAP measure) was $81 million.Development capital expenditures totaled $20 million; Free cash flow(1) (non-GAAP measure) was $59 million.Net loss totaled $70 million, or $1.38 per diluted share. Adjusted net income(1) (non-GA...

May 6, 2021 May 6, 2021 1 EN

GlobeNewsWire

Denbury Announces Executive Leadership Appointment for Denbury Carbon Solutions Team

Denbury Announces Executive Leadership Appointment for Denbury Carbon Solutions Team Company Studying a Significant Expansion in System Capacity PLANO, Texas, April 26, 2021 (GLOBE NEWSWIRE) -- In order to further advance the Company’s strategic vision and direction for its Carbon Capture, Use and Storage (CCUS) business, Denbury Inc. (NYSE: DEN) (“Denbury” or the “Company”) today announced the appointment of Nikulas Wood as Senior Vice President. Mr. Wood will head the Denbury Carbon Solutions team and report directly to Denbury Chief Executive Officer, Chris Kendall. The Denbury Carbo...

April 26, 2021 April 26, 2021 1 EN

discoverIE Group - FY24 EPS in line; good margin progress

discoverIE anticipates reporting FY24 underlying EPS in line with board expectations. After a period in mid-FY24 of working down inventory, customers appear to be reverting to normal ordering patterns, with Q424 organic revenue growth of 2% y-o-y and 11% q-o-q and a strong pipeline of design wins at year-end. We have revised our forecasts to reflect lower revenue, partly due to a disposal, but maintain our profit forecasts, which results in operating margin expansion in FY24 and FY25.

21h / 59m 21h / 59m 1 EN

Sean Conroy

Sean Conroy

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

April 18, 2024 April 18, 2024 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

April 18, 2024 April 18, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN